[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adrenal-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adrenal-metastases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100371352","stereotactic-magnetic-resonance-guided-radiation-therapy-100371352",false,"NCT04115254","Stereotactic Magnetic Resonance Guided Radiation Therapy","A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)","Inclusion Criteria:\n\n* Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.\n* Tumor size ≤ 7cm\n* Age 18 years of older.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Specific eligibility requirements for each disease site with be covered in each specific cohort.\n\nExclusion Criteria:\n\n* Specific exclusion requirements for each disease site with be covered in each specific cohort\n* History of allergic reactions attributed to gadolinium-based IV contrast.\n\n  \\-- Note: If a patient will not receive contrast, this is not applicable\n* Pregnant women are excluded from this study.\n* Severe claustrophobia or anxiety\n* Participants who cannot undergo an MRI","ALL","18 Years",{"count":19,"type":20},397,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.\n\n* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.\n* Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Pancreas Cancer","Lung Cancer","Renal Cancer","Adrenal Metastases","Prostate Cancer","Liver Metastases","Oligoprogressive Nodal Metastases","Metachronous Nodal Metastases","Synchronous Nodal Metastases","Mesothelioma","Spine Metastases","Brain Metastases","Borderline Resectable Pancreatic Carcinoma",[40,41,26,27,28,29,30,31,42,43,44,45,46,47],"Magnetic Resonance Imaging (MRI)","MRIdian Linear Accelerator","Oligoprogressive","Metachronous","Synchronous","Spine","Prostate Boost","Pelvic Re Irradiation","RECRUITING","2025-11-11",{"date":51,"type":52},"2025-11-13","ACTUAL",{"date":54,"type":52},"2019-10-22",{"date":56,"type":20},"2028-06",{"name":58,"class":59},"Dana-Farber Cancer Institute","OTHER",2]